https://trial.medpath.com/news/otc-markets-hosts-virtual-investor-presentation-with-christian-kanstrup-ceo-of-evaxion 2024-10-11T18:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/otc-markets-hosts-virtual-investor-presentation-with-christian-kanstrup-ceo-of-evaxion 2024-10-11T18:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lmp744-for-glioma-onclive 2024-10-11T18:45:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-lmp744-for-glioma-onclive 2024-10-11T18:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trials-begin-in-newcastle-for-pancreatic-cancer-patients-nbn-news 2024-10-11T18:36:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trials-begin-in-newcastle-for-pancreatic-cancer-patients-nbn-news 2024-10-11T18:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sees-no-need-for-dccr-advisory-committee-meeting-prader-willi-syndrome-news 2024-10-11T18:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-sees-no-need-for-dccr-advisory-committee-meeting-prader-willi-syndrome-news 2024-10-11T18:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/uzedy-reducing-the-risk-of-relapse-in-patients-with-schizophrenia-psychiatric-times 2024-10-11T18:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uzedy-reducing-the-risk-of-relapse-in-patients-with-schizophrenia-psychiatric-times 2024-10-11T18:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-finds-multidisciplinary-approach-improves-quality-of-life-for-movement-disorder-patients 2024-10-11T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-finds-multidisciplinary-approach-improves-quality-of-life-for-movement-disorder-patients 2024-10-11T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-guidelines-for-mpn-reflect-new-drugs-focus-on-clinical-trials 2024-10-11T17:53:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-guidelines-for-mpn-reflect-new-drugs-focus-on-clinical-trials 2024-10-11T17:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-new-hemophilia-drug-hympavzi-gains-fda-approval-investing-com 2024-10-11T17:50:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-new-hemophilia-drug-hympavzi-gains-fda-approval-investing-com 2024-10-11T17:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/acticor-biotech-repositions-glenzocimab-in-the-treatment-of-myocardial-infarction 2024-10-11T17:38:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acticor-biotech-repositions-glenzocimab-in-the-treatment-of-myocardial-infarction 2024-10-11T17:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-foundationone-r-liquid-cdx-as-a-companion 2024-10-11T16:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-approves-foundationone-r-liquid-cdx-as-a-companion 2024-10-11T16:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/sublingual-epinephrine-film-moving-forward-nda-anticipated-by-early-next-year-healio 2024-10-11T16:22:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sublingual-epinephrine-film-moving-forward-nda-anticipated-by-early-next-year-healio 2024-10-11T16:22:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-elinzanetant-nda-for-menopause-symptoms-and-other-health-updates 2024-10-11T16:15:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-elinzanetant-nda-for-menopause-symptoms-and-other-health-updates 2024-10-11T16:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/popliteal-plexus-block-compared-with-tibial-nerve-block-on-rehabilitation-goals-following-total 2024-10-11T16:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/popliteal-plexus-block-compared-with-tibial-nerve-block-on-rehabilitation-goals-following-total 2024-10-11T16:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-roche-breast-cancer-drug-turnstone-lays-off-60-of-staff-biopharma-dive 2024-10-11T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-roche-breast-cancer-drug-turnstone-lays-off-60-of-staff-biopharma-dive 2024-10-11T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-drugs-like-ozempic-may-protect-brain-health-several-studies-show 2024-10-11T16:11:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-drugs-like-ozempic-may-protect-brain-health-several-studies-show 2024-10-11T16:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-breakthrough-study-unveils-new-culprits-that-could-revolutionize-treatment-approaches 2024-10-11T15:56:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-breakthrough-study-unveils-new-culprits-that-could-revolutionize-treatment-approaches 2024-10-11T15:56:11+00:00 weekly 0.7 https://trial.medpath.com/news/mirum-pharmaceuticals-volixibat-garners-buy-rating-amidst-breakthrough-therapy 2024-10-11T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-volixibat-garners-buy-rating-amidst-breakthrough-therapy 2024-10-11T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-obesity-drug-on-track-for-japan-approval-next-year-ceo-nikkei-asia 2024-10-11T15:25:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-obesity-drug-on-track-for-japan-approval-next-year-ceo-nikkei-asia 2024-10-11T15:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-expects-pneumonia-drug-approval-in-india-soon-cnbc-tv18 2024-10-11T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-expects-pneumonia-drug-approval-in-india-soon-cnbc-tv18 2024-10-11T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/an-antigen-discovery-pipeline-integrates-multi-omics-data-and-informs-immunotherapy 2024-10-11T15:18:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-antigen-discovery-pipeline-integrates-multi-omics-data-and-informs-immunotherapy 2024-10-11T15:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-gets-favourable-recommendation-from-cdsco-for-antibiotic-for-cabp 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-gets-favourable-recommendation-from-cdsco-for-antibiotic-for-cabp 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-new-test-treatment-for-endometriosis 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-for-new-test-treatment-for-endometriosis 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/disruption-of-asxl1-gene-improves-tumor-control-in-immunotherapy 2024-10-11T15:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disruption-of-asxl1-gene-improves-tumor-control-in-immunotherapy 2024-10-11T15:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/sintilimab-bevacizumab-in-relapsed-or-persistent-ovarian-clear-cell-carcinoma 2024-10-11T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sintilimab-bevacizumab-in-relapsed-or-persistent-ovarian-clear-cell-carcinoma 2024-10-11T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-therapeutics-shares-retain-buy-rating-post-roche-deal-investing-com 2024-10-11T14:57:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempest-therapeutics-shares-retain-buy-rating-post-roche-deal-investing-com 2024-10-11T14:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/admi-applauds-india-s-decision-to-maintain-stringent-clinical-trial-requirements-for-ivds 2024-10-11T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/admi-applauds-india-s-decision-to-maintain-stringent-clinical-trial-requirements-for-ivds 2024-10-11T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/graded-oral-challenge-safe-effective-for-pediatric-macrolide-allergy-hcplive 2024-10-11T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/graded-oral-challenge-safe-effective-for-pediatric-macrolide-allergy-hcplive 2024-10-11T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/aha-advocates-for-expanded-lipoprotein-apheresis-use-in-high-risk-cardiovascular-patients 2024-10-11T14:00:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-advocates-for-expanded-lipoprotein-apheresis-use-in-high-risk-cardiovascular-patients 2024-10-11T14:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/viltepso-r-viltolarsen-injection-phase-ii-study-galactic53-trial-data-published-in 2024-10-11T13:56:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viltepso-r-viltolarsen-injection-phase-ii-study-galactic53-trial-data-published-in 2024-10-11T13:56:21+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-denali-abandon-mid-stage-multiple-sclerosis-study-on-disappointing-data 2024-10-11T13:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-denali-abandon-mid-stage-multiple-sclerosis-study-on-disappointing-data 2024-10-11T13:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-announces-initial-patient-dosing-in-globenewswire 2024-10-11T13:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-announces-initial-patient-dosing-in-globenewswire 2024-10-11T13:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/expert-outlines-key-factors-in-selecting-car-t-cell-therapies-for-follicular-lymphoma 2024-10-11T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-outlines-key-factors-in-selecting-car-t-cell-therapies-for-follicular-lymphoma 2024-10-11T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and 2024-10-11T12:50:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and 2024-10-11T12:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/harm-effects-in-non-registered-versus-registered-randomized-controlled-trials-of-medications 2024-10-11T12:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harm-effects-in-non-registered-versus-registered-randomized-controlled-trials-of-medications 2024-10-11T12:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/patient-advocate-led-study-reveals-need-for-dosing-reform-in-metastatic-breast-cancer 2024-10-11T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-advocate-led-study-reveals-need-for-dosing-reform-in-metastatic-breast-cancer 2024-10-11T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-reports-new-positive-results-on-biomarkers-and-safety-in-can10-phase-1-clinical-study 2024-10-11T10:15:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-reports-new-positive-results-on-biomarkers-and-safety-in-can10-phase-1-clinical-study 2024-10-11T10:15:13+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-of-a-tissue-agnostic-genome-wide-methylome-enrichment-molecular-pubmed 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-validation-of-a-tissue-agnostic-genome-wide-methylome-enrichment-molecular-pubmed 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/clario-partners-with-pathai-to-enhance-efficiency-in-gi-clinical-trials-yahoo 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clario-partners-with-pathai-to-enhance-efficiency-in-gi-clinical-trials-yahoo 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/hivr4p-2024-research-highlights-reproductive-health-while-on-prep-and-signals-to-hiv-gov 2024-10-11T08:59:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hivr4p-2024-research-highlights-reproductive-health-while-on-prep-and-signals-to-hiv-gov 2024-10-11T08:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/lixisenatide-shows-promise-in-early-parkinson-s-disease-treatment-trial 2024-10-11T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixisenatide-shows-promise-in-early-parkinson-s-disease-treatment-trial 2024-10-11T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/sclc-staging-determines-treatment-adverse-events-oncology-nursing-news 2024-10-11T07:04:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sclc-staging-determines-treatment-adverse-events-oncology-nursing-news 2024-10-11T07:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/clonal-evolution-study-reveals-treatment-patterns-in-lower-risk-mds-patients 2024-10-11T06:55:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clonal-evolution-study-reveals-treatment-patterns-in-lower-risk-mds-patients 2024-10-11T06:55:49+00:00 weekly 0.7 https://trial.medpath.com/news/nih-names-3-hubs-for-primary-care-clinical-research-network-healthcare-innovation 2024-10-11T05:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-names-3-hubs-for-primary-care-clinical-research-network-healthcare-innovation 2024-10-11T05:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/ruanjian-qingmai-granules-for-the-treatment-of-early-symptomatic-peri-ijgm 2024-10-11T05:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruanjian-qingmai-granules-for-the-treatment-of-early-symptomatic-peri-ijgm 2024-10-11T05:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/experts-debate-optimal-sequencing-of-adcs-in-her2-low-metastatic-breast-cancer-treatment 2024-10-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-debate-optimal-sequencing-of-adcs-in-her2-low-metastatic-breast-cancer-treatment 2024-10-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nmpa-grants-marketing-approval-to-the-first-co-developed-ngs-based-companion 2024-10-11T04:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmpa-grants-marketing-approval-to-the-first-co-developed-ngs-based-companion 2024-10-11T04:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/eu-authority-mulls-paying-for-late-stage-research-as-a-pull-incentive-for-neglected-pink-sheet 2024-10-11T04:30:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-authority-mulls-paying-for-late-stage-research-as-a-pull-incentive-for-neglected-pink-sheet 2024-10-11T04:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-deep-brain-stimulation-trial-results-poised-to-transform-parkinson-s-disease 2024-10-11T04:24:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-deep-brain-stimulation-trial-results-poised-to-transform-parkinson-s-disease 2024-10-11T04:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/specialty-pharmacies-and-ambulatory-infusion-centers-drive-healthcare-cost-savings-and-enhanced-patient-experience 2024-10-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/specialty-pharmacies-and-ambulatory-infusion-centers-drive-healthcare-cost-savings-and-enhanced-patient-experience 2024-10-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-enters-talks-with-cd-r-for-16-4b-consumer-health-unit-sale 2024-10-11T03:47:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-enters-talks-with-cd-r-for-16-4b-consumer-health-unit-sale 2024-10-11T03:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research-biospace 2024-10-11T03:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research-biospace 2024-10-11T03:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/hussman-institute-alzheimer-s-experts-lead-apoe4-research-at-nih-meeting-inventum 2024-10-11T03:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hussman-institute-alzheimer-s-experts-lead-apoe4-research-at-nih-meeting-inventum 2024-10-11T03:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-new-drug-suppresses-systemic-inflammatory-response-syndrome-resulting-from 2024-10-11T02:29:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-new-drug-suppresses-systemic-inflammatory-response-syndrome-resulting-from 2024-10-11T02:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/booster-therapeutics-launches-with-15m-to-develop-novel-proteasome-activator-platform-for-neurodegenerative-diseases 2024-10-11T02:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/booster-therapeutics-launches-with-15m-to-develop-novel-proteasome-activator-platform-for-neurodegenerative-diseases 2024-10-11T02:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/molecularly-targeted-therapeutics-are-precisely-aimed-onclive 2024-10-11T02:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecularly-targeted-therapeutics-are-precisely-aimed-onclive 2024-10-11T02:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/vanqua-s-parkinson-s-drug-shows-promise-as-company-initiates-phase-ib-study 2024-10-11T01:49:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanqua-s-parkinson-s-drug-shows-promise-as-company-initiates-phase-ib-study 2024-10-11T01:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/dong-a-st-s-stelara-biosimilar-imuldosa-scores-fda-approval-pharma-article-kbr 2024-10-11T01:44:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dong-a-st-s-stelara-biosimilar-imuldosa-scores-fda-approval-pharma-article-kbr 2024-10-11T01:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-breakthrough-boosts-heart-patient-hopes-mirage-news 2024-10-10T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-breakthrough-boosts-heart-patient-hopes-mirage-news 2024-10-10T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/high-concentration-mabs-present-manufacturing-challenges-as-demand-surges-reports-cphi-europe 2024-10-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-concentration-mabs-present-manufacturing-challenges-as-demand-surges-reports-cphi-europe 2024-10-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bofa-securities-reiterates-buy-rating-on-alnylam-stock-highlights-amvuttra-launch-strategy 2024-10-10T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bofa-securities-reiterates-buy-rating-on-alnylam-stock-highlights-amvuttra-launch-strategy 2024-10-10T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/let-s-talk-breast-density-cancer-movies-and-music-treatment-induced-aging 2024-10-10T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/let-s-talk-breast-density-cancer-movies-and-music-treatment-induced-aging 2024-10-10T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-heads-to-phase-3-with-melanoma-cell-therapy-seeks-to-raise-150m 2024-10-10T21:42:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-heads-to-phase-3-with-melanoma-cell-therapy-seeks-to-raise-150m 2024-10-10T21:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/an-interactive-game-for-people-suffering-from-nerve-pain-is-heading-to-clinical-trials 2024-10-10T21:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-interactive-game-for-people-suffering-from-nerve-pain-is-heading-to-clinical-trials 2024-10-10T21:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-off-to-phase-iii-with-ima203-after-positive-melanoma-results-scrip-citeline 2024-10-10T21:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-off-to-phase-iii-with-ima203-after-positive-melanoma-results-scrip-citeline 2024-10-10T21:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-thursday-oct-10-2024-genentech 2024-10-10T21:09:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-thursday-oct-10-2024-genentech 2024-10-10T21:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/drug-rivals-face-off-in-pbc-after-fda-hands-down-2-new-approvals-1-advisory-snub-healio 2024-10-10T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-rivals-face-off-in-pbc-after-fda-hands-down-2-new-approvals-1-advisory-snub-healio 2024-10-10T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/drugmakers-are-racing-to-find-the-next-wegovy-these-obesity-trials-are-ones-to-watch 2024-10-10T20:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drugmakers-are-racing-to-find-the-next-wegovy-these-obesity-trials-are-ones-to-watch 2024-10-10T20:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-egfr-vegf-inhibition-slows-advanced-egfr-positive-lung-cancer 2024-10-10T19:53:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-egfr-vegf-inhibition-slows-advanced-egfr-positive-lung-cancer 2024-10-10T19:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/the-first-ever-antiviral-treatment-for-rsv-american-council-on-science-and-health 2024-10-10T19:27:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-first-ever-antiviral-treatment-for-rsv-american-council-on-science-and-health 2024-10-10T19:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/sotigalimab-may-be-a-safe-and-feasible-addition-to-the-rectal-cancer-chemoradiotherapy 2024-10-10T19:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotigalimab-may-be-a-safe-and-feasible-addition-to-the-rectal-cancer-chemoradiotherapy 2024-10-10T19:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease 2024-10-10T19:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease 2024-10-10T19:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-opportunity-for-afib-patients-who-don-t-take-an-anticoagulant-blood-clots 2024-10-10T18:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-opportunity-for-afib-patients-who-don-t-take-an-anticoagulant-blood-clots 2024-10-10T18:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/cyrus-biotechnology-congratulates-david-baker-2024-nobel-laureate-in-chemistry-and 2024-10-10T18:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyrus-biotechnology-congratulates-david-baker-2024-nobel-laureate-in-chemistry-and 2024-10-10T18:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/hawai-i-cancer-consortium-expands-clinical-trial-access-to-address-healthcare-disparities-in-pacific-islands 2024-10-10T17:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hawai-i-cancer-consortium-expands-clinical-trial-access-to-address-healthcare-disparities-in-pacific-islands 2024-10-10T17:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/stronger-safety-considerations-needed-for-lumateprone-use-especially-for-women 2024-10-10T17:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stronger-safety-considerations-needed-for-lumateprone-use-especially-for-women 2024-10-10T17:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-hospitals-research-unit-receives-ps1m-funding-bbc 2024-10-10T17:25:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-hospitals-research-unit-receives-ps1m-funding-bbc 2024-10-10T17:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-iota-biosciences-ide-approval-for-first-in-human-early-feasibility-study-with 2024-10-10T17:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-iota-biosciences-ide-approval-for-first-in-human-early-feasibility-study-with 2024-10-10T17:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/bimekizumab-demonstrates-safety-and-efficacy-in-elderly-patients-with-psoriasis 2024-10-10T17:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bimekizumab-demonstrates-safety-and-efficacy-in-elderly-patients-with-psoriasis 2024-10-10T17:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/sensorium-therapeutics-highlights-promising-data-on-lead-assets-targeting-anxiety 2024-10-10T16:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensorium-therapeutics-highlights-promising-data-on-lead-assets-targeting-anxiety 2024-10-10T16:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/bayesian-approaches-in-drug-development-continuing-the-virtuous-cycle-nature 2024-10-10T16:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayesian-approaches-in-drug-development-continuing-the-virtuous-cycle-nature 2024-10-10T16:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/happy-health-receives-fda-clearance-for-smart-ring-mobihealthnews 2024-10-10T15:44:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/happy-health-receives-fda-clearance-for-smart-ring-mobihealthnews 2024-10-10T15:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-modern-retina 2024-10-10T15:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-modern-retina 2024-10-10T15:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-first-of-its-kind-stent-for-neonates-very-young-with-pulmonary-stenosis-approved 2024-10-10T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-first-of-its-kind-stent-for-neonates-very-young-with-pulmonary-stenosis-approved 2024-10-10T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-may-improve-treatment-response-in-pancreatic-cancer 2024-10-10T14:52:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-therapy-may-improve-treatment-response-in-pancreatic-cancer 2024-10-10T14:52:26+00:00 weekly 0.7 https://trial.medpath.com/news/what-you-should-know-about-breakthrough-hiv-drug-futurity 2024-10-10T14:41:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-you-should-know-about-breakthrough-hiv-drug-futurity 2024-10-10T14:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-on-the-intervention-effect-of-digital-therapy-on-children-with-attention-deficit 2024-10-10T14:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-study-on-the-intervention-effect-of-digital-therapy-on-children-with-attention-deficit 2024-10-10T14:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-stock-titan 2024-10-10T14:38:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-stock-titan 2024-10-10T14:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/antag-therapeutics-gets-fda-clearance-to-start-clinical-trials-with-new-obesity-drug 2024-10-10T14:34:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antag-therapeutics-gets-fda-clearance-to-start-clinical-trials-with-new-obesity-drug 2024-10-10T14:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/forget-epipens-this-san-diego-biotech-is-offering-the-same-medicine-without-needles 2024-10-10T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/forget-epipens-this-san-diego-biotech-is-offering-the-same-medicine-without-needles 2024-10-10T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/7-children-receiving-bluebird-s-gene-therapy-developed-blood-cancers-study 2024-10-10T14:17:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-children-receiving-bluebird-s-gene-therapy-developed-blood-cancers-study 2024-10-10T14:17:10+00:00 weekly 0.7 https://trial.medpath.com/news/benmelstobart-plus-anlotinib-in-patients-with-egfr-positive-advanced-nsclc-after-failure-of 2024-10-10T14:16:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benmelstobart-plus-anlotinib-in-patients-with-egfr-positive-advanced-nsclc-after-failure-of 2024-10-10T14:16:35+00:00 weekly 0.7 https://trial.medpath.com/news/grant-supports-gene-editing-research-for-rare-metabolic-diseases-news-medical 2024-10-10T14:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grant-supports-gene-editing-research-for-rare-metabolic-diseases-news-medical 2024-10-10T14:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-phase-iii-prostate-cancer-win-builds-case-for-broader-label-for-talzenna-xtandi-combo 2024-10-10T14:04:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-phase-iii-prostate-cancer-win-builds-case-for-broader-label-for-talzenna-xtandi-combo 2024-10-10T14:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-biospace 2024-10-10T13:58:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-biospace 2024-10-10T13:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-analysis-of-durable-responses-on-immune-checkpoint-inhibitors-versus-other 2024-10-10T13:52:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-analysis-of-durable-responses-on-immune-checkpoint-inhibitors-versus-other 2024-10-10T13:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/antibiotic-duo-effective-against-drug-resistant-infections-study-kff-health-news 2024-10-10T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibiotic-duo-effective-against-drug-resistant-infections-study-kff-health-news 2024-10-10T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/highly-targeted-approach-supports-als-gene-therapy-development-als-news-today 2024-10-10T13:27:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highly-targeted-approach-supports-als-gene-therapy-development-als-news-today 2024-10-10T13:27:38+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to 2024-10-10T13:27:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to 2024-10-10T13:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-approaches-to-tki-dosing-allow-for-treatment-free-remissions-and-reduced 2024-10-10T13:25:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tailored-approaches-to-tki-dosing-allow-for-treatment-free-remissions-and-reduced 2024-10-10T13:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100-tipranks 2024-10-10T13:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100-tipranks 2024-10-10T13:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-pbc 2024-10-10T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-pbc 2024-10-10T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-announces-completion-of-enrollment-in-orca-ol-clinical-trial-biospace 2024-10-10T13:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/achieve-life-sciences-announces-completion-of-enrollment-in-orca-ol-clinical-trial-biospace 2024-10-10T13:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/movano-health-provides-update-on-fda-review-of-eviemed-ring-move-stock-news 2024-10-10T12:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-health-provides-update-on-fda-review-of-eviemed-ring-move-stock-news 2024-10-10T12:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/international-myeloma-foundation-launches-clinical-trial-globenewswire 2024-10-10T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-myeloma-foundation-launches-clinical-trial-globenewswire 2024-10-10T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/attain-phase-iii-study-of-etirinotecan-pegol-versus-treatment-of-physician-s-choice-in 2024-10-10T12:46:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attain-phase-iii-study-of-etirinotecan-pegol-versus-treatment-of-physician-s-choice-in 2024-10-10T12:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/ai-simulations-help-drug-trials-forbes 2024-10-10T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-simulations-help-drug-trials-forbes 2024-10-10T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/melt-pharmaceuticals-announces-dosing-of-last-patient-in-pivotal-phase-3-study-of-its-lead 2024-10-10T12:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-pharmaceuticals-announces-dosing-of-last-patient-in-pivotal-phase-3-study-of-its-lead 2024-10-10T12:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicentric-randomized-controlled-clinical-trial-to-study-the-impact-of-bedside-model 2024-10-10T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multicentric-randomized-controlled-clinical-trial-to-study-the-impact-of-bedside-model 2024-10-10T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-r-vs-stock-titan 2024-10-10T12:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-r-vs-stock-titan 2024-10-10T12:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/micrornas-won-the-nobel-will-they-ever-be-useful-as-medicines-nature 2024-10-10T12:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/micrornas-won-the-nobel-will-they-ever-be-useful-as-medicines-nature 2024-10-10T12:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-phase-ii-study-of-veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus 2024-10-10T11:55:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-phase-ii-study-of-veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus 2024-10-10T11:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/priovant-mulls-broad-autoimmune-indications-for-brepacitinib-clinical-trials-arena 2024-10-10T11:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/priovant-mulls-broad-autoimmune-indications-for-brepacitinib-clinical-trials-arena 2024-10-10T11:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-therapeutics-partners-with-roche-on-cancer-trial-investing-com 2024-10-10T11:41:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempest-therapeutics-partners-with-roche-on-cancer-trial-investing-com 2024-10-10T11:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-announced-phase-1-clinical-trial-in-australia-hellenic-suffers-further-funding 2024-10-10T11:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-announced-phase-1-clinical-trial-in-australia-hellenic-suffers-further-funding 2024-10-10T11:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-group-announces-start-of-phase-ii-clinical-trial-globenewswire 2024-10-10T11:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharming-group-announces-start-of-phase-ii-clinical-trial-globenewswire 2024-10-10T11:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on 2024-10-10T10:48:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on 2024-10-10T10:48:17+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-study-identifies-new-targets-for-combating-drug-resistant-cancer-the-statesman 2024-10-10T10:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-study-identifies-new-targets-for-combating-drug-resistant-cancer-the-statesman 2024-10-10T10:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/could-lingering-infection-be-causing-long-covid 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-lingering-infection-be-causing-long-covid 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/new-life-changing-myeloma-drug-approved-for-fourth-line-use-on-the-nhs-for-those 2024-10-10T10:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-life-changing-myeloma-drug-approved-for-fourth-line-use-on-the-nhs-for-those 2024-10-10T10:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/bridget-koontz-md-18f-flotufolastat-demonstrates-high-detection-rate-in-low-psa-setting 2024-10-10T10:01:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridget-koontz-md-18f-flotufolastat-demonstrates-high-detection-rate-in-low-psa-setting 2024-10-10T10:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/experts-emphasize-early-detection-and-personalized-treatment-advances-during-breast-cancer-awareness-month 2024-10-10T10:00:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-emphasize-early-detection-and-personalized-treatment-advances-during-breast-cancer-awareness-month 2024-10-10T10:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/diamedica-gets-sahpra-approval-for-phase-ii-preeclampsia-treatment-trial-yahoo-finance 2024-10-10T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamedica-gets-sahpra-approval-for-phase-ii-preeclampsia-treatment-trial-yahoo-finance 2024-10-10T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-10-10T09:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-10-10T09:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/low-cost-blood-drug-saves-thousands-of-trauma-patients-lives-nihr 2024-10-10T08:49:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-cost-blood-drug-saves-thousands-of-trauma-patients-lives-nihr 2024-10-10T08:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/study-uncovers-mechanism-of-mx-protein-in-fighting-hiv-1-and-herpes-simplex-virus 2024-10-10T08:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-uncovers-mechanism-of-mx-protein-in-fighting-hiv-1-and-herpes-simplex-virus 2024-10-10T08:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/alzecure-pharma-broadcasts-live-event-about-the-phase-ii-candidate-acd440-against 2024-10-10T08:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzecure-pharma-broadcasts-live-event-about-the-phase-ii-candidate-acd440-against 2024-10-10T08:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/ab-science-revenues-for-the-first-half-of-2024-and-update-globenewswire 2024-10-10T06:36:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ab-science-revenues-for-the-first-half-of-2024-and-update-globenewswire 2024-10-10T06:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/harbour-biomed-announces-publication-of-the-phase-i-study-results-for-porustobart-morningstar 2024-10-10T06:36:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harbour-biomed-announces-publication-of-the-phase-i-study-results-for-porustobart-morningstar 2024-10-10T06:36:21+00:00 weekly 0.7 https://trial.medpath.com/news/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa 2024-10-10T06:03:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa 2024-10-10T06:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-s-phase-ii-results-published-in-clinical-cancer-research-marketscreener 2024-10-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-s-phase-ii-results-published-in-clinical-cancer-research-marketscreener 2024-10-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-final-rule-on-laboratory-tests-reshapes-medical-start-up-landscape 2024-10-10T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-final-rule-on-laboratory-tests-reshapes-medical-start-up-landscape 2024-10-10T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-models-show-promise-in-pulmonary-embolism-diagnosis-doximitygpt-achieves-70-accuracy 2024-10-10T05:14:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-models-show-promise-in-pulmonary-embolism-diagnosis-doximitygpt-achieves-70-accuracy 2024-10-10T05:14:34+00:00 weekly 0.7 https://trial.medpath.com/news/protein-prediction-wins-chemistry-nobel-alnylam-submits-an-all-important-drug-application 2024-10-10T04:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protein-prediction-wins-chemistry-nobel-alnylam-submits-an-all-important-drug-application 2024-10-10T04:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-completes-v-wave-acquisition-cardiovascular-business 2024-10-10T03:37:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-completes-v-wave-acquisition-cardiovascular-business 2024-10-10T03:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/gummy-drug-delivery-systems-show-promise-for-patient-compliance-face-manufacturing-challenges 2024-10-10T03:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gummy-drug-delivery-systems-show-promise-for-patient-compliance-face-manufacturing-challenges 2024-10-10T03:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/activist-investor-starboard-claims-former-pfizer-executives-faced-threats-over-support-for-company-reform 2024-10-10T03:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/activist-investor-starboard-claims-former-pfizer-executives-faced-threats-over-support-for-company-reform 2024-10-10T03:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/namodenoson-earns-fda-orphan-drug-designation-in-pancreatic-cancer 2024-10-10T03:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/namodenoson-earns-fda-orphan-drug-designation-in-pancreatic-cancer 2024-10-10T03:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/arda-therapeutics-raises-43m-series-a-to-advance-novel-cell-depletion-platform-for-chronic-diseases 2024-10-10T02:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arda-therapeutics-raises-43m-series-a-to-advance-novel-cell-depletion-platform-for-chronic-diseases 2024-10-10T02:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/eversana-s-direct-to-patient-model-revolutionizes-healthcare-access-through-digital-innovation 2024-10-10T01:23:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eversana-s-direct-to-patient-model-revolutionizes-healthcare-access-through-digital-innovation 2024-10-10T01:23:38+00:00 weekly 0.7 https://trial.medpath.com/news/purplelab-to-host-webinar-on-data-driven-physician-prescribing-analysis-and-kol-engagement 2024-10-10T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purplelab-to-host-webinar-on-data-driven-physician-prescribing-analysis-and-kol-engagement 2024-10-10T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/how-tecelra-r-approval-is-transforming-tcr-t-cell-therapy-news-medical 2024-10-10T00:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-tecelra-r-approval-is-transforming-tcr-t-cell-therapy-news-medical 2024-10-10T00:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-large-study-to-tackle-type-2-diabetes-in-young-people 2024-10-10T00:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-large-study-to-tackle-type-2-diabetes-in-young-people 2024-10-10T00:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/dusseldorf-upc-ruling-clarifies-imminent-infringement-standards-for-biosimilars 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dusseldorf-upc-ruling-clarifies-imminent-infringement-standards-for-biosimilars 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intra-arterial-pressure-enabled-drug-delivery-enhances-liver-tumor-treatment 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intra-arterial-pressure-enabled-drug-delivery-enhances-liver-tumor-treatment 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emis-wins-innovation-award-for-revolutionary-clinical-trial-recruitment-platform 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emis-wins-innovation-award-for-revolutionary-clinical-trial-recruitment-platform 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-clinical-trials-show-promise-in-reducing-costs-despite-implementation-challenges 2024-10-09T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-clinical-trials-show-promise-in-reducing-costs-despite-implementation-challenges 2024-10-09T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-20-rehabilitation-project-entering-phase-3-shreveport-ksla 2024-10-09T22:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-20-rehabilitation-project-entering-phase-3-shreveport-ksla 2024-10-09T22:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy-clinical-trials-arena 2024-10-09T22:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy-clinical-trials-arena 2024-10-09T22:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/kalivir-doses-first-subject-in-phase-i-ib-solid-tumour-treatment-trial 2024-10-09T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalivir-doses-first-subject-in-phase-i-ib-solid-tumour-treatment-trial 2024-10-09T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/nurse-led-pilot-aims-to-improve-patient-access-to-clinical-trials-nursing-times 2024-10-09T21:50:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurse-led-pilot-aims-to-improve-patient-access-to-clinical-trials-nursing-times 2024-10-09T21:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-fra-vsc-q2-2024-earnings-call-highlights-strategic-advances-amid-financial 2024-10-09T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-ag-fra-vsc-q2-2024-earnings-call-highlights-strategic-advances-amid-financial 2024-10-09T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-launches-avalus-ultra-valve-in-western-europe-at-eacts-congress 2024-10-09T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-launches-avalus-ultra-valve-in-western-europe-at-eacts-congress 2024-10-09T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-clears-way-for-phase-iii-after-positive-cls-ax-results-in-wet-amd-scrip 2024-10-09T21:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-clears-way-for-phase-iii-after-positive-cls-ax-results-in-wet-amd-scrip 2024-10-09T21:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-inc-reports-promising-results-for-annamycin-in-aml-treatment 2024-10-09T21:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-biotech-inc-reports-promising-results-for-annamycin-in-aml-treatment 2024-10-09T21:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/ai-biotech-insitro-partners-with-lilly-on-metabolic-disease-drugs-endpoints-news 2024-10-09T20:53:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-biotech-insitro-partners-with-lilly-on-metabolic-disease-drugs-endpoints-news 2024-10-09T20:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/a-walk-in-her-flip-flops-el-centro-mayor-shares-story-of-kidney-cancer 2024-10-09T20:28:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-walk-in-her-flip-flops-el-centro-mayor-shares-story-of-kidney-cancer 2024-10-09T20:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/liu-s-insights-on-navigating-the-fragility-of-phase-3-trials-targeted-oncology 2024-10-09T19:03:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liu-s-insights-on-navigating-the-fragility-of-phase-3-trials-targeted-oncology 2024-10-09T19:03:17+00:00 weekly 0.7 https://trial.medpath.com/news/complex-randomization-delivered-successfully-clinical-leader 2024-10-09T18:48:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complex-randomization-delivered-successfully-clinical-leader 2024-10-09T18:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-sunitinib-plus-exemestane-in-post-menopausal-women-with-hormone-receptor 2024-10-09T18:06:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-sunitinib-plus-exemestane-in-post-menopausal-women-with-hormone-receptor 2024-10-09T18:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/news/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/news/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/news/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/news/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/news/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/news/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/news/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/biosergen-completes-enrollment-of-first-cohort-in-bsg005-proof-of-concept-trial 2024-10-07T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosergen-completes-enrollment-of-first-cohort-in-bsg005-proof-of-concept-trial 2024-10-07T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-announces-phase-i-results-for-a-first-of-its-kind-macrocyclic-manganese 2024-10-07T06:44:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ge-healthcare-announces-phase-i-results-for-a-first-of-its-kind-macrocyclic-manganese 2024-10-07T06:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/avillion-announces-positive-high-level-results-from-phase-globenewswire 2024-10-07T06:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avillion-announces-positive-high-level-results-from-phase-globenewswire 2024-10-07T06:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-of-interdisciplinary-evaluation-in-non-arthritic-hip-pain-a-randomized-trial 2024-10-07T06:21:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-of-interdisciplinary-evaluation-in-non-arthritic-hip-pain-a-randomized-trial 2024-10-07T06:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-to-prevent-food-allergies-in-children-opens-king-s-college-london 2024-10-07T06:15:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trial-to-prevent-food-allergies-in-children-opens-king-s-college-london 2024-10-07T06:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/imu-biosciences-joins-ground-breaking-uk-research-globenewswire 2024-10-07T06:06:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imu-biosciences-joins-ground-breaking-uk-research-globenewswire 2024-10-07T06:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/airsupra-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-the-risk 2024-10-07T06:05:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airsupra-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-the-risk 2024-10-07T06:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/addition-to-scientific-advisory-board-company-announcement-investegate 2024-10-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-to-scientific-advisory-board-company-announcement-investegate 2024-10-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/formulary-barriers-and-rebate-structures-hinder-adalimumab-biosimilar-adoption-in-us-market 2024-10-07T05:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formulary-barriers-and-rebate-structures-hinder-adalimumab-biosimilar-adoption-in-us-market 2024-10-07T05:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-faricimab-in-treatment-naive-neovascular-age-related-macular-degeneration 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-faricimab-in-treatment-naive-neovascular-age-related-macular-degeneration 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-novel-procedure-for-treating-radial-keratotomy-rk-induced-corneal-opth 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-novel-procedure-for-treating-radial-keratotomy-rk-induced-corneal-opth 2024-10-07T04:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/can-cb1-inhibitors-make-a-comeback-in-obesity-biospace 2024-10-07T04:27:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-cb1-inhibitors-make-a-comeback-in-obesity-biospace 2024-10-07T04:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-triples-hiv-prevention-drug-supply-for-low-income-nations 2024-10-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-triples-hiv-prevention-drug-supply-for-low-income-nations 2024-10-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/renal-denervation-up-to-date-2024-evidence-and-perspectives-in-japan-nature 2024-10-07T03:55:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renal-denervation-up-to-date-2024-evidence-and-perspectives-in-japan-nature 2024-10-07T03:55:30+00:00 weekly 0.7 https://trial.medpath.com/news/concerns-have-been-raised-about-obesity-treatments-which-are-attracting-attention-due-to-the-effect 2024-10-07T02:45:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/concerns-have-been-raised-about-obesity-treatments-which-are-attracting-attention-due-to-the-effect 2024-10-07T02:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/productlife-group-expands-drug-development-capabilities-with-intiquan-acquisition 2024-10-07T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/productlife-group-expands-drug-development-capabilities-with-intiquan-acquisition 2024-10-07T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-use-of-up-to-three-tubes-of-biofrontera-inc-s-ameluz-aminolevulinic-acid-hci-topical-gel-10-in-one-treatment 2024-10-07T02:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-use-of-up-to-three-tubes-of-biofrontera-inc-s-ameluz-aminolevulinic-acid-hci-topical-gel-10-in-one-treatment 2024-10-07T02:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/preventing-antimicrobial-resistance-not-states-centre-may-approve-new-antibiotics-blue 2024-10-07T01:41:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preventing-antimicrobial-resistance-not-states-centre-may-approve-new-antibiotics-blue 2024-10-07T01:41:56+00:00 weekly 0.7 https://trial.medpath.com/news/health-check-long-suffering-mesoblast-investors-dare-to-dream-stockhead 2024-10-07T01:04:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-check-long-suffering-mesoblast-investors-dare-to-dream-stockhead 2024-10-07T01:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-biosciences-2g-colostat-colorectal-cancer-detection-kit-outperforms-predecessor 2024-10-07T00:27:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rhythm-biosciences-2g-colostat-colorectal-cancer-detection-kit-outperforms-predecessor 2024-10-07T00:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-licensing-deals-surge-to-3-8-billion-as-major-pharma-companies-bet-on-technology-s-future 2024-10-07T00:12:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-licensing-deals-surge-to-3-8-billion-as-major-pharma-companies-bet-on-technology-s-future 2024-10-07T00:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-s-temtokibart-shows-comparable-efficacy-to-dupilumab-in-phase-2a-atopic-dermatitis-trial 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-pharma-s-temtokibart-shows-comparable-efficacy-to-dupilumab-in-phase-2a-atopic-dermatitis-trial 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/simtra-biopharma-solutions-invests-14m-to-expand-adc-manufacturing-capabilities 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simtra-biopharma-solutions-invests-14m-to-expand-adc-manufacturing-capabilities 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-raises-eur15-million-series-c-round-to 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-raises-eur15-million-series-c-round-to 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuron-welcomes-nmrc-results-for-campylobacter-in-controlled-human-infection-model-study 2024-10-06T23:10:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuron-welcomes-nmrc-results-for-campylobacter-in-controlled-human-infection-model-study 2024-10-06T23:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/personalised-radiotherapy-for-people-with-bladder-cancer-shows-promise 2024-10-06T23:01:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalised-radiotherapy-for-people-with-bladder-cancer-shows-promise 2024-10-06T23:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/judo-bio-launches-with-100m-to-pioneer-kidney-targeted-rna-therapeutics 2024-10-06T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/judo-bio-launches-with-100m-to-pioneer-kidney-targeted-rna-therapeutics 2024-10-06T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-enrols-first-participant-in-phase-iib-crohn-s-disease-drug-trial-msn 2024-10-06T21:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abivax-enrols-first-participant-in-phase-iib-crohn-s-disease-drug-trial-msn 2024-10-06T21:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/sammy-basso-progeria-advocate-has-died-at-28-stat-news 2024-10-06T21:14:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sammy-basso-progeria-advocate-has-died-at-28-stat-news 2024-10-06T21:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-approaches-to-safety-profile-development-in-rare-disease-clinical-trials 2024-10-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-approaches-to-safety-profile-development-in-rare-disease-clinical-trials 2024-10-06T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-crucial-for-personalized-treatment-in-metastatic-nsclc-experts-emphasize 2024-10-06T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-testing-crucial-for-personalized-treatment-in-metastatic-nsclc-experts-emphasize 2024-10-06T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arca-receives-fda-fast-track-designation-for-gencarotm-development-quick-facts 2024-10-06T19:49:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arca-receives-fda-fast-track-designation-for-gencarotm-development-quick-facts 2024-10-06T19:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatology-month-in-review-september-2024-hcplive 2024-10-06T19:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rheumatology-month-in-review-september-2024-hcplive 2024-10-06T19:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/india-denies-clinical-trial-waivers-for-in-vitro-diagnostics-despite-global-approvals 2024-10-06T19:10:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-denies-clinical-trial-waivers-for-in-vitro-diagnostics-despite-global-approvals 2024-10-06T19:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-nlx-112-orphan-medicinal-product-designation-neurologylive 2024-10-06T19:05:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-nlx-112-orphan-medicinal-product-designation-neurologylive 2024-10-06T19:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-to-combat-debilitating-immune-system-disorder-lupus-the-condition-that-left-seal-scarred 2024-10-06T18:23:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-to-combat-debilitating-immune-system-disorder-lupus-the-condition-that-left-seal-scarred 2024-10-06T18:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/policy-support-important-as-india-largely-an-out-of-pocket-market-panchal 2024-10-06T17:37:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/policy-support-important-as-india-largely-an-out-of-pocket-market-panchal 2024-10-06T17:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharmaceutical-industry-gets-cdsco-panel-nod-to-study-aflibercept-injection 2024-10-06T17:25:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sun-pharmaceutical-industry-gets-cdsco-panel-nod-to-study-aflibercept-injection 2024-10-06T17:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-co-ltd-announces-unblinding-of-data-from-phase-iii-clinical-trial-of-iterative 2024-10-06T16:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aim-vaccine-co-ltd-announces-unblinding-of-data-from-phase-iii-clinical-trial-of-iterative 2024-10-06T16:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-are-a-transformative-prehabilitation-tool-for-weight-loss-in-obese 2024-10-06T15:42:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-are-a-transformative-prehabilitation-tool-for-weight-loss-in-obese 2024-10-06T15:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-to-present-radicava-ors-r-edaravone-pr-newswire 2024-10-06T14:53:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-america-to-present-radicava-ors-r-edaravone-pr-newswire 2024-10-06T14:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/science-medicine-studying-the-chemical-miscommunication-that-may-lead-to-obesity 2024-10-06T14:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-medicine-studying-the-chemical-miscommunication-that-may-lead-to-obesity 2024-10-06T14:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/human-papillomavirus-hpv-induced-cancers-first-patient-enrolled-in-phase-i-iia-clinical-trial 2024-10-06T14:04:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/human-papillomavirus-hpv-induced-cancers-first-patient-enrolled-in-phase-i-iia-clinical-trial 2024-10-06T14:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/london-clinical-trial-targets-lingering-covid-toll-on-patients-smell-distortion 2024-10-06T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/london-clinical-trial-targets-lingering-covid-toll-on-patients-smell-distortion 2024-10-06T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/medication-increases-radiation-therapy-s-efficacy-for-lung-cancer-that-has-progressed-to-brain 2024-10-06T13:42:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medication-increases-radiation-therapy-s-efficacy-for-lung-cancer-that-has-progressed-to-brain 2024-10-06T13:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/cedric-pobel-md-phenotypic-and-genomic-analyses-from-peace-1-in-de-novo-mcspc 2024-10-06T13:21:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cedric-pobel-md-phenotypic-and-genomic-analyses-from-peace-1-in-de-novo-mcspc 2024-10-06T13:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/immix-and-nexcella-make-progress-in-us-trial-for-light-chain-amyloidosis-car-t-nxc-201 2024-10-06T13:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-and-nexcella-make-progress-in-us-trial-for-light-chain-amyloidosis-car-t-nxc-201 2024-10-06T13:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/fractional-doses-of-pneumococcal-vaccine-could-bolster-supply-in-under-resourced-regions 2024-10-06T12:48:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fractional-doses-of-pneumococcal-vaccine-could-bolster-supply-in-under-resourced-regions 2024-10-06T12:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/otsuka-reports-data-from-phase-iii-alzheimer-s-agitation-trial-msn 2024-10-06T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/otsuka-reports-data-from-phase-iii-alzheimer-s-agitation-trial-msn 2024-10-06T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/tifr-study-uses-psychedelic-drug-to-trace-neuron-that-can-reduce-anxiety-times-of-india 2024-10-06T09:22:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tifr-study-uses-psychedelic-drug-to-trace-neuron-that-can-reduce-anxiety-times-of-india 2024-10-06T09:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-to-study-efficacy-of-metformin-inositol-in-pcos-treatment-the-economic-times 2024-10-06T04:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-to-study-efficacy-of-metformin-inositol-in-pcos-treatment-the-economic-times 2024-10-06T04:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/meta-correlation-of-the-effect-of-ketamine-and-psilocybin-induced-subjective-effects-on 2024-10-06T03:37:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-correlation-of-the-effect-of-ketamine-and-psilocybin-induced-subjective-effects-on 2024-10-06T03:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-chemotherapy-doses-lead-to-better-outcomes-in-high-risk-breast-cancer 2024-10-06T03:01:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tailored-chemotherapy-doses-lead-to-better-outcomes-in-high-risk-breast-cancer 2024-10-06T03:01:25+00:00 weekly 0.7 https://trial.medpath.com/news/deadly-venom-of-funnel-web-spiders-used-to-develop-breakthrough-drug-for-heart-attack-patients 2024-10-06T02:53:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deadly-venom-of-funnel-web-spiders-used-to-develop-breakthrough-drug-for-heart-attack-patients 2024-10-06T02:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/nme8-is-essential-for-protection-against-chemotherapy-drug-cisplatin-induced-male 2024-10-06T01:56:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nme8-is-essential-for-protection-against-chemotherapy-drug-cisplatin-induced-male 2024-10-06T01:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-lung-cancer-drug-offers-hope-as-precision-medicine-advances-shia-waves 2024-10-06T01:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-lung-cancer-drug-offers-hope-as-precision-medicine-advances-shia-waves 2024-10-06T01:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-immune-responses-to-neoadjuvant-fulvestrant-with-or-without-enzalutamide-in-er-her2 2024-10-06T01:20:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-immune-responses-to-neoadjuvant-fulvestrant-with-or-without-enzalutamide-in-er-her2 2024-10-06T01:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-cancer-treatment-now-accessible-for-hundreds-more-aussies-as-prices-slashed 2024-10-06T01:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-cancer-treatment-now-accessible-for-hundreds-more-aussies-as-prices-slashed 2024-10-06T01:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/eu-the-johnson-and-johnson-vaccine-has-a-possible-link-with-blood-clotting-telegraph 2024-10-06T00:23:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-the-johnson-and-johnson-vaccine-has-a-possible-link-with-blood-clotting-telegraph 2024-10-06T00:23:05+00:00 weekly 0.7 https://trial.medpath.com/news/research-seeks-to-establish-the-efficacy-of-minimally-invasive-breast-cancer-procedures-and-tests 2024-10-05T22:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-seeks-to-establish-the-efficacy-of-minimally-invasive-breast-cancer-procedures-and-tests 2024-10-05T22:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/pelabresib-and-ruxolitinib-show-benefit-in-treating-patients-with-jak-inhibitor-naive-myelofibrosis 2024-10-05T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pelabresib-and-ruxolitinib-show-benefit-in-treating-patients-with-jak-inhibitor-naive-myelofibrosis 2024-10-05T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/lenacapavir-a-breakthrough-in-hiv-prevention-but-challenges-in-access-remai 2024-10-05T21:52:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenacapavir-a-breakthrough-in-hiv-prevention-but-challenges-in-access-remai 2024-10-05T21:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-use-of-ultra-hypofractionated-rt-in-elderly-breast-cancer 2024-10-05T21:38:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-use-of-ultra-hypofractionated-rt-in-elderly-breast-cancer 2024-10-05T21:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/relationship-between-sleep-and-pain-the-hippocratic-post 2024-10-05T21:25:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relationship-between-sleep-and-pain-the-hippocratic-post 2024-10-05T21:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/u-of-virginia-researchers-explore-new-ways-to-manage-diabetes-wtop-news 2024-10-05T20:52:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-of-virginia-researchers-explore-new-ways-to-manage-diabetes-wtop-news 2024-10-05T20:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-1-first-in-human-study-evaluating-safety-pharmacokinetics-and-efficacy-of-abbv 2024-10-05T20:03:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-1-first-in-human-study-evaluating-safety-pharmacokinetics-and-efficacy-of-abbv 2024-10-05T20:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-infectious-disease-news-stories-week-of-september-27-october-4-contagion-live 2024-10-05T19:42:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-infectious-disease-news-stories-week-of-september-27-october-4-contagion-live 2024-10-05T19:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/vamorolone-shows-potential-dual-mechanism-as-mineralcorticoid-receptor-antagonist-in 2024-10-05T19:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vamorolone-shows-potential-dual-mechanism-as-mineralcorticoid-receptor-antagonist-in 2024-10-05T19:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/suven-life-sciences-to-present-positive-results-from-phase-2a-proof-of-concept-study-of-ropanicant 2024-10-05T17:32:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suven-life-sciences-to-present-positive-results-from-phase-2a-proof-of-concept-study-of-ropanicant 2024-10-05T17:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-doctors-hope-new-cannabis-drug-will-help-cancer-patients-gain-weight-inews 2024-10-05T17:24:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-doctors-hope-new-cannabis-drug-will-help-cancer-patients-gain-weight-inews 2024-10-05T17:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-gets-fda-approval-for-pnh-drug-voydeya-msn 2024-10-05T17:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-gets-fda-approval-for-pnh-drug-voydeya-msn 2024-10-05T17:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/horizon-study-update-for-msa-drug-ion464-onaboutlinumtoxina-to-be-tested-in-essential 2024-10-05T17:07:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/horizon-study-update-for-msa-drug-ion464-onaboutlinumtoxina-to-be-tested-in-essential 2024-10-05T17:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-persistence-safety-after-switching-to-infliximab-biosimilars-in-canadians-with-ibd 2024-10-05T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-persistence-safety-after-switching-to-infliximab-biosimilars-in-canadians-with-ibd 2024-10-05T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/this-healthcare-growth-stock-could-be-a-steal-of-a-deal-right-now-the-globe-and-mail 2024-10-05T16:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-healthcare-growth-stock-could-be-a-steal-of-a-deal-right-now-the-globe-and-mail 2024-10-05T16:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-gsk-pfizer-moderna-rsv-vaccines-available-for-older-adults-60-fortune-well 2024-10-05T16:27:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-gsk-pfizer-moderna-rsv-vaccines-available-for-older-adults-60-fortune-well 2024-10-05T16:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/urinary-cyclophilin-a-as-an-early-marker-of-chronic-kidney-disease-with-underlying-type-2-diabetes 2024-10-05T16:15:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urinary-cyclophilin-a-as-an-early-marker-of-chronic-kidney-disease-with-underlying-type-2-diabetes 2024-10-05T16:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/rural-iowa-mothers-face-severe-postpartum-depression-news-kmaland-com 2024-10-05T14:50:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rural-iowa-mothers-face-severe-postpartum-depression-news-kmaland-com 2024-10-05T14:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/secukinumab-surpasses-ustekinumab-in-clearing-skin-for-generalized-pustular-psoriasis 2024-10-05T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secukinumab-surpasses-ustekinumab-in-clearing-skin-for-generalized-pustular-psoriasis 2024-10-05T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-could-extend-the-lives-of-breast-cancer-patients-news-medical 2024-10-05T14:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-could-extend-the-lives-of-breast-cancer-patients-news-medical 2024-10-05T14:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-of-india-s-first-covid-19-vaccine-to-start-with-375-people-the-commune 2024-10-05T13:54:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-of-india-s-first-covid-19-vaccine-to-start-with-375-people-the-commune 2024-10-05T13:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/1-ai-biotech-stock-that-just-scored-a-major-milestone-the-globe-and-mail 2024-10-05T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1-ai-biotech-stock-that-just-scored-a-major-milestone-the-globe-and-mail 2024-10-05T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-discontinues-study-for-investigational-antiviral-for-dengue-prevention-contagion-live 2024-10-05T10:52:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-discontinues-study-for-investigational-antiviral-for-dengue-prevention-contagion-live 2024-10-05T10:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/department-of-defense-funded-research-may-lea-eurekalert 2024-10-05T09:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/department-of-defense-funded-research-may-lea-eurekalert 2024-10-05T09:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/matching-adjusted-indirect-comparison-of-the-efficacy-and-safety-of-difamilast-1-and 2024-10-05T09:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matching-adjusted-indirect-comparison-of-the-efficacy-and-safety-of-difamilast-1-and 2024-10-05T09:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-trial-stalls-due-to-fund-crunch-the-daily-star 2024-10-05T08:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaccine-trial-stalls-due-to-fund-crunch-the-daily-star 2024-10-05T08:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-receives-fda-clearance-for-alzheimer-s-imaging-tool-hit-consultant 2024-10-05T08:10:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-clearance-for-alzheimer-s-imaging-tool-hit-consultant 2024-10-05T08:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-october-4-2024 2024-10-05T07:08:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-october-4-2024 2024-10-05T07:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/valbenazine-shows-sustained-treatment-effect-on-huntington-s-chorea-in-kinect-hd2 2024-10-05T07:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valbenazine-shows-sustained-treatment-effect-on-huntington-s-chorea-in-kinect-hd2 2024-10-05T07:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-october-4-2024 2024-10-05T07:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-friday-5-october-4-2024 2024-10-05T07:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/novel-anti-estrogen-therapies-are-poised-to-expand-treatment-options-in-advanced-er 2024-10-05T06:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-anti-estrogen-therapies-are-poised-to-expand-treatment-options-in-advanced-er 2024-10-05T06:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/inside-information-bioretec-updates-its-product-development-strategy-by-accelerating-the 2024-10-05T06:34:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inside-information-bioretec-updates-its-product-development-strategy-by-accelerating-the 2024-10-05T06:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-drug-could-make-tooth-loss-a-thing-of-the-past-by-2030-news18 2024-10-05T05:21:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-drug-could-make-tooth-loss-a-thing-of-the-past-by-2030-news18 2024-10-05T05:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-pos-and-roi-an-alphabet-soup-of-21st-century-drug-development-life-science-leader 2024-10-05T05:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-pos-and-roi-an-alphabet-soup-of-21st-century-drug-development-life-science-leader 2024-10-05T05:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/dear-payers-people-living-with-early-alzheimer-s-disease-are-worth-it-medical-economics 2024-10-05T05:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dear-payers-people-living-with-early-alzheimer-s-disease-are-worth-it-medical-economics 2024-10-05T05:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-roflumilast-cream-0-15-for-ad-with-eric-simpson-md-mcr-faad 2024-10-05T05:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-roflumilast-cream-0-15-for-ad-with-eric-simpson-md-mcr-faad 2024-10-05T05:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/i-spy-2-2-is-working-why-aren-t-others-replicating-the-design-biocentury 2024-10-05T05:06:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-spy-2-2-is-working-why-aren-t-others-replicating-the-design-biocentury 2024-10-05T05:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-plus-platinum-doublet-and-maintenance-niraparib-for-late-relapsing 2024-10-05T04:01:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-plus-platinum-doublet-and-maintenance-niraparib-for-late-relapsing 2024-10-05T04:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/9-months-of-treatment-with-tralokinumab-results-in-improved-qol-itch-and-sleep 2024-10-05T03:47:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/9-months-of-treatment-with-tralokinumab-results-in-improved-qol-itch-and-sleep 2024-10-05T03:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/an-investigator-s-perspective-on-biomarker-guided-antibiotic-treatment-contagion-live 2024-10-05T03:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-investigator-s-perspective-on-biomarker-guided-antibiotic-treatment-contagion-live 2024-10-05T03:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/gut-bacteria-engineered-to-act-as-tumor-gps-for-immunotherapies-medical-xpress 2024-10-05T03:30:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gut-bacteria-engineered-to-act-as-tumor-gps-for-immunotherapies-medical-xpress 2024-10-05T03:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-to-lay-off-10-of-workforce-biospace 2024-10-05T03:24:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-to-lay-off-10-of-workforce-biospace 2024-10-05T03:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-relapsed-or-refractory-acute-lymphocytic-leukemia-all-nct06481735 2024-10-05T01:53:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-relapsed-or-refractory-acute-lymphocytic-leukemia-all-nct06481735 2024-10-05T01:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-announces-kva12123-abstract-accepted-for-poster-globenewswire 2024-10-05T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kineta-announces-kva12123-abstract-accepted-for-poster-globenewswire 2024-10-05T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/oral-paltusotine-demonstrates-efficacy-in-phase-3-acromegaly-trial-offering-alternative-to-injectable-treatments 2024-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-paltusotine-demonstrates-efficacy-in-phase-3-acromegaly-trial-offering-alternative-to-injectable-treatments 2024-10-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-blood-test-improves-early-diagnosis-of-pancreatic-cancer-news-medical 2024-10-04T23:41:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-blood-test-improves-early-diagnosis-of-pancreatic-cancer-news-medical 2024-10-04T23:41:44+00:00 weekly 0.7 https://trial.medpath.com/news/why-avidity-biosciences-zoomed-to-a-12-gain-this-week-the-globe-and-mail 2024-10-04T23:20:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-avidity-biosciences-zoomed-to-a-12-gain-this-week-the-globe-and-mail 2024-10-04T23:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-rna-stock-surges-on-fda-decision-gurufocus 2024-10-04T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-rna-stock-surges-on-fda-decision-gurufocus 2024-10-04T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/boy-with-duchenne-s-gets-gene-therapy-3-days-before-he-s-ineligible-exclusive 2024-10-04T22:40:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boy-with-duchenne-s-gets-gene-therapy-3-days-before-he-s-ineligible-exclusive 2024-10-04T22:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/novel-radioconjugate-or-conventional-care-prior-to-allogeneic-hematopoietic-cell 2024-10-04T22:37:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-radioconjugate-or-conventional-care-prior-to-allogeneic-hematopoietic-cell 2024-10-04T22:37:33+00:00 weekly 0.7 https://trial.medpath.com/news/tranexamic-acid-during-radical-cystectomy-a-randomized-clinical-trial-urotoday 2024-10-04T22:30:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tranexamic-acid-during-radical-cystectomy-a-randomized-clinical-trial-urotoday 2024-10-04T22:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-rt-improves-biochemical-recurrence-outcomes-in-prostate-cancer 2024-10-04T21:53:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-rt-improves-biochemical-recurrence-outcomes-in-prostate-cancer 2024-10-04T21:53:08+00:00 weekly 0.7 https://trial.medpath.com/news/island-pharmaceuticals-trials-prevention-and-therapy-benefit-of-dengue-drug 2024-10-04T21:10:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/island-pharmaceuticals-trials-prevention-and-therapy-benefit-of-dengue-drug 2024-10-04T21:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/dr-machaalani-on-the-incidence-of-erbb2-amplifications-across-race-sex-and-cancer-type 2024-10-04T21:07:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-machaalani-on-the-incidence-of-erbb2-amplifications-across-race-sex-and-cancer-type 2024-10-04T21:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/cms-initiates-coverage-review-for-abbott-triclip-system-massdevice 2024-10-04T18:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cms-initiates-coverage-review-for-abbott-triclip-system-massdevice 2024-10-04T18:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-antibody 2024-10-04T18:42:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-antibody 2024-10-04T18:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/ema-reviews-hair-loss-products-following-concerns-about-suicidal-thoughts 2024-10-04T18:28:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-reviews-hair-loss-products-following-concerns-about-suicidal-thoughts 2024-10-04T18:28:07+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-egfr-mutation-ctdna-dynamics-in-patients-with-advanced-egfr-mutated-nsclc 2024-10-04T17:37:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plasma-egfr-mutation-ctdna-dynamics-in-patients-with-advanced-egfr-mutated-nsclc 2024-10-04T17:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/onco360-r-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra 2024-10-04T17:32:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onco360-r-has-been-selected-as-the-national-specialty-pharmacy-partner-for-tevimbra 2024-10-04T17:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/opdivo-gets-perioperative-approval-pharmas-cut-jobs-in-new-jersey-ireland 2024-10-04T17:16:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opdivo-gets-perioperative-approval-pharmas-cut-jobs-in-new-jersey-ireland 2024-10-04T17:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-r-announces-key-progress-and-upcoming-studies-for-breast-pr-newswire 2024-10-04T17:00:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytics-biotech-r-announces-key-progress-and-upcoming-studies-for-breast-pr-newswire 2024-10-04T17:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/global-mrna-cancer-vaccine-clinical-trial-fda-approval-globenewswire 2024-10-04T16:56:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-mrna-cancer-vaccine-clinical-trial-fda-approval-globenewswire 2024-10-04T16:56:58+00:00 weekly 0.7